Board of Directors

Sung Chul Kim, PhD., LSKB President

Dr. Kim brings 26 years of drug development experience covering areas such as pharmaceutical product development, non-clinical studies, clinical trials, cGMP manufacturing, Korean and US regulatory affairs, as well as business development.


Alex Kim, MA., LSKB E.V.P., Corporate Dev.

Mr. Kim has 25 years experience in the pharmaceutical industry. Mr. Kim’s experience includes executive management, business development, product and technology licensing, strategic planning, fund raising and M&A activity.


Soo Whan Choi, PhD., LSKB CFO

Dr. Choi has over 20 years experience in the pharmaceutical industry. He is a successful corporate leader combining a strong background in business development, fundraising, M&A activity, and operations.


Ha Young Kim, HLB Executive Director

Mr. Kim joined the Board of Directors in 2012. He is currently an Executive Director of HLB Life Science Co., a Korea-based company mainly engaged in the energy service company (ESCO) business and renewable energy business, and since October 2013 has been serving as Executive Director of Life Liver Co., a biotechnology company, develops bio artificial liver for treatment of severe liver diseases.


Anton Gueth

Mr. Gueth joined the Board of Directors as an independent member in 2018. He was previously a Managing Director of Burrill Securities, and since October 2014 has been serving as Managing Director of EVOLUTION Life Science Partners.